Creative Medical Technology Holdings
- Company typePublic
- Founded2011
- HeadquartersPhoenix, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Creative Medical Technology Holdings firmographics
Firmographics- Name
- Creative Medical Technology Holdings
- Legal name
- Creative Medical Technology Holdings, Inc.
- Website
- https://creativemedicaltechnology.com
- Company type
- Public
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Creative Medical Technology Holdings industry classification
Industry- Product category
- Regenerative Medicine
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industries
- Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Nephrology & Urology Pharmaceuticals (HLAIAAAM), Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)
Keywords
Where Creative Medical Technology Holdings is headquartered
LocationHeadquarters
- HQ city
- Phoenix
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Creative Medical Technology Holdings business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- CELZ-201 Cell Therapy: The company is advancing CELZ-201 (Olastrocel) through clinical trials for chronic lower back pain and Type 1 Diabetes. Revenue will be generated upon FDA approval and commercialization of the cell therapy product.
- CaverStem Kits: Minimal product revenues of $6,000 from CaverStem kits in fiscal year 2025, representing the only current commercial product revenue.
- Research Collaborations: The company works with Not For Profit and For Profit Organizations in further development of technologies through translational projects with defined policies allowing indirect costs up to 25 percent of direct costs.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Per visit | Clinical trial participant reimbursement |
| Other | Other | Expanded Access pricing |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Creative Medical Technology Holdings product offering
Product offeringCore offering
Creative Medical Technology Holdings is a clinical-stage biotechnology company developing proprietary regenerative medicine and immunotherapy platforms (AlloStem, ImmCelz, iPScelz) that power multiple clinical programs including CELZ-201 (Olastrocel) for Type 1 Diabetes and chronic lower back pain, rapid autologous therapies (StemSpine, OvaStem, CaverStem) for orthopedic and urological conditions, and the AI-driven Project PHOENIX registry for burn pit-exposed veterans. The company holds FDA Fast Track designation for CELZ-201-DDT, FDA Orphan Drug Designation for ImmCelz, and WHO INN approvals for olastrocel and etaroleucel.
Product overview
Creative Medical Technology Holdings is a biotechnology company advancing a portfolio of regenerative medicine and immunotherapy platforms across immunology, endocrinology, urogynecology, and orthopedics. The company's core technology platforms include AlloStem™ (enhanced allogenic cell platform using Perinatal Tissue Derived Cells), ImmCelz® (supercharged autologous immunotherapy), and iPScelz™ (cellular reprogramming). These platforms power multiple named clinical programs: CELZ-201 (Olastrocel/etaroleucel) for type 1 diabetes and chronic lower back pain; AlloStemSpine for degenerative disc disease; Alova for premature ovarian failure; and CELZ-100 (ImmCelz®) for immunotherapy applications. The company also offers rapid autologous therapies — StemSpine®, OvaStem®, and CaverStem® — for orthopedic and urological conditions, and has recently launched Project PHOENIX, an AI-driven virtual registry for toxic exposure research. FDA Fast Track designation (CELZ-201-DDT) and Orphan Drug Designation (ImmCelz®) support key programs.
Differentiator
Problem solved
Functional benefit
Brands
- AlloStem: Enhanced allogenic cell platform composed of Perinatal Tissue Derived Cells (PTDCs) providing immediately available, scalable 'Universal' recipient products without any requirement of immunosuppression.
- ImmCelz
- iPScelz
- StemSpine
- OvaStem
- CaverStem
Products and services
- AlloStem Enhanced allogeneic cell platform composed of Perinatal Tissue Derived Cells (PTDCs) providing immediately available, scalable universal-recipient cell products without requiring immunosuppression. Forms the foundation for the CELZ-201 and AlloStemSpine clinical programs.
- ImmCelz Supercharged autologous immunotherapy platform that utilizes secreted factors from AlloStem cells to reprogram the patient's own immune cells. FDA-granted Orphan Drug Designation. Powers the CELZ-100 clinical program across multiple indications.
- iPScelz Cellular reprogramming platform that harnesses the ability to make any cell type in the body from any human being, producing the human adult version of the embryonic stem cell without ethical, legal, or safety issues.
- CELZ-201 (Olastrocel) Allogeneic regenerative cell therapy derived from Perinatal Tissue Derived Cells, currently in Phase I/IIa clinical trials for newly diagnosed Type 1 Diabetes (CREATE-1 trial, 18 patients enrolled) and chronic lower back pain associated with degenerative disc disease (ADAPT trial). Received FDA Fast Track designation in August 2025.
- StemSpine Rapid autologous stem cell therapy for the treatment of lower back pain using bone marrow aspirate harvested from the patient, with no rejection or immunosuppression required.
- OvaStem Rapid autologous stem cell therapy targeting infertility as a result of premature ovarian failure, utilizing the patient's own stem cells to stimulate natural healing and improve ovarian function.
- CaverStem Rapid autologous stem cell therapy for erectile dysfunction using bone marrow-derived stem cells. Generated minimal product revenues of $6,000 from kit sales in fiscal year 2025.
- Project PHOENIX IRB-approved, AI-driven virtual registry platform designed to collect health data from at least 1,000 U.S. veterans exposed to burn pits and toxic environmental hazards, utilizing mobile-app data collection with AI-driven multi-omics profiling for biomarker discovery and therapeutic development. Operated through the BioDefense Veterans Initiative in partnership with Greenstone Biosciences.
- Ultrasome Cell-free regenerative therapy derived from GMP-manufactured CELZ-201 product. Achieved a 93% response rate in a knee osteoarthritis pilot study with clinically meaningful improvements in mobility and pain reduction and no serious adverse events. Targets over 30 million U.S. adults affected by osteoarthritis.
- AlloStemSpine (CELZ-201-DDT) Investigational allogeneic umbilical cord-derived mesenchymal stem cell therapy (also branded CELZ-201-DDT) for chronic lower back pain due to degenerative disc disease. FDA Fast Track designation granted August 2025. Expanded Access program available under IND 029792. Currently in ADAPT Phase 1/2a trial, with 180-day interim results showing 15.3-point ODI improvement (p=0.0003).
- CELZ-101 (Etaroleucel) Autologous regulatory T-cell immunotherapy program targeting Type 1 diabetes in pancreatic islet transplantation, with proposed WHO International Nonproprietary Name 'etaroleucel' published in Proposed INN List 134. Marks the company's second WHO INN milestone.
- Alova Clinical program utilizing the AlloStem platform to treat infertility as a result of premature ovarian failure.
- CELZ-Biodefense Toxic Exposure Atlas Proprietary platform integrating multi-omics profiling to support biomarker discovery and therapeutic development for veterans and future populations exposed to toxic hazards, supporting the BioDefense Veterans Initiative.
Quantifiable outcome
- 15.3-point improvement on Oswestry Disability Index (p=0.0003) and 3.9-point reduction in pain scores at 180-day interim results for CELZ-201 in chronic lower back pain
- +2 more outcomes
Companies that use Creative Medical Technology Holdings
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles5 records
Creative Medical Technology Holdings technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature6 records
Creative Medical Technology Holdings partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Greenstone BiosciencescorePartnership with Greenstone Biosciences to develop molecular and cellular data analysis systems for the BioDefense Veterans Initiative (Project PHOENIX). The collaboration aims to create predictive models and treatments for U.S. veterans exposed to burn pits and toxic environmental hazards, utilizing AI-integrated regenerative biodefense as a component of national health security.
Scale indicators8 records
Recent moves6 records
Expansion highlights5 records
Creative Medical Technology Holdings competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key highlights7 records
Customer concentration
Creative Medical Technology Holdings social profiles
Digital presenceCreative Medical Technology Holdings compliance and trust
Trust signalCompliance2 records
Creative Medical Technology Holdings financial estimates
Financial estimateRevenue estimate
Valuation estimate
Creative Medical Technology Holdings leadership team
Management profileNumber of profiles
Profiles6 records
Creative Medical Technology Holdings funding detail
Funding detailFunding overview
Funding rounds3 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Creative Medical Technology Holdings M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Creative Medical Technology Holdings
What does Creative Medical Technology Holdings do?
Creative Medical Technology Holdings is a clinical-stage biotechnology company developing proprietary regenerative medicine and immunotherapy platforms (AlloStem, ImmCelz, iPScelz) that power multiple clinical programs including CELZ-201 (Olastrocel) for Type 1 Diabetes and chronic lower back pain, rapid autologous therapies (StemSpine, OvaStem, CaverStem) for orthopedic and urological conditions, and the AI-driven Project PHOENIX registry for burn pit-exposed veterans. The company holds FDA Fast Track designation for CELZ-201-DDT, FDA Orphan Drug Designation for ImmCelz, and WHO INN approvals for olastrocel and etaroleucel.
Is Creative Medical Technology Holdings a public or private company?
Creative Medical Technology Holdings is a public company. It is classified as public and is currently operating.
When was Creative Medical Technology Holdings founded?
Creative Medical Technology Holdings was founded in 2011. It employs 1 to 10 people.
Where is Creative Medical Technology Holdings based?
Creative Medical Technology Holdings is headquartered in Phoenix, United States, in the North America region.
How does Creative Medical Technology Holdings make money?
Three revenue lines are on record. CELZ-201 Cell Therapy is the primary driver. The others are caverStem Kits and research Collaborations.
Does Creative Medical Technology Holdings have an API?
No public API is recorded for Creative Medical Technology Holdings.
What industry is Creative Medical Technology Holdings in?
Creative Medical Technology Holdings's product category is Regenerative Medicine. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 325414 and its SIC code is 2834.